GlassScriptPhysician profile
Maurice Roulhac
NPI 1801837109
$1,330.67
in general payments reported to CMS, 2019-2025
10 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $67.34 · 2022: $480 · 2023: $226 · 2024: $306 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $528.27 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Medtronic, INC. | $373.49 | 2022-2024 | Abre |
| Boston Scientific Corporation | $98.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $77.74 | 2022 | |
| Polynovo North America LLC | $71.95 | 2024 | Novosorb Btm |
| Cook Medical LLC | $67.34 | 2020 | |
| Medtronic Vascular, INC. | $42.58 | 2019 | |
| Cvrx, INC. | $35.30 | 2025 | Barostim Neo System |
| Penumbra, INC. | $22.73 | 2024 | Indigo System |
| Becton, Dickinson and Company | $13.14 | 2024 | Venovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Roulhac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.